Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies

Thomas A. Fox, Amy A. Kirkwood, Louise Enfield, Maeve O'Reilly, Suzanne Arulogun, Shirley D'Sa, Jenny O'Nions, Janki Kavi, Evan Vitsaras, William Townsend, Siobhan O. Burns, Satyen H. Gohil, Kate Cwynarski, Kirsty J. Thomson, Mahdad Noursadeghi, Robert S. Heyderman, Tommy Rampling, Kirit M. Ardeshna, Laura E. McCoy, Emma C. Morris*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusAccepted/In press - 2021
Externally publishedYes

Bibliographical note

Funding Information:
This study is supported by the National Institute for Health Research (NIHR) University College London Hospitals NHS Foundation Trust (UCLH) Biomedical Research Centre and Blood Cancer UK. Robert S. Heyderman is a NIHR Senior Investigator. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Keywords

  • B-cell malignancy
  • CAR-T
  • COVID-19
  • vaccination

Cite this